Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT

Pytlik Robert; Vackova Blanka; Konirova Eva; Trnkova Marie; Blahovcova Petra; Pohlreich David; Polgarova Kamila; Klener Pavel Jr.; Benesova Katerina; Kopeckova Katerina; Pirnos Jan; Trneny Marek

首页> 外文期刊>Bone marrow transplantation >Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT

【24h】

Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT

机译：转移/难治性NHL的老年患者的长期结果提到ASCT

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Bone marrow transplantation》 |2021年第3期|共4页
作者
Pytlik Robert; Vackova Blanka; Konirova Eva; Trnkova Marie; Blahovcova Petra; Pohlreich David; Polgarova Kamila; Klener Pavel Jr.; Benesova Katerina; Kopeckova Katerina; Pirnos Jan; Trneny Marek;
展开▼
作者单位

Inst Hematol &

Blood Transfus Dept Cell Therapy Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

Univ Hosp Motol Dept Oncol Prague Czech Republic;

Hosp Ceske Budejovice Dept Oncol Ceske Budejovice Czech Republic;

Charles Univ Prague Med Fac 1 Dept Med Hematol 1 Prague Czech Republic;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. A Study Protocol on the Evaluation of Referral Strategies for Inflammatory Arthritis in Primary Care Patients at the Level of Healthcare Organization, Patient Relevant Outcomes and Costs [J] . Elke Theodora Antonia Maria van Delft, Deirisa Lopes Barreto, Jan Arno Matteo Roeterink, 健康（英文） . 2020,第003期
2. Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin＇s lymphoma： single institution experience [J] . Bufei, Wang, Huiqiang, 中德临床肿瘤学杂志：英文版 . 2006,第006期
3. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience [J] . Ciochetto Chiara, Botto Barbara, Passera Roberto, Annals of hematology . 2018,第9期

机译：Yttrium-90 ibritumomab Tiuxetan（Zevalin）随后是梁（Z-梁）调节方案和自体干细胞移植（ASCT）复发或难治性高风险B细胞非霍奇金淋巴瘤（NHL）：一种机构意大利经验
4. Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma [J] . Ramaswami R., Pria A. Dalla, Parker K., Bone marrow transplantation . 2016,第12期

机译：复发/难治性HIV相关淋巴瘤患者自体干细胞移植（ASCT）的结果
5. Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-na?ve patients [J] . Kirill V. Lepik Leukemia and lymphoma . 2019,第9a10期

机译：Nivolumab用于治疗复发和难治性经典霍奇金淋巴瘤，ASCT和ASCT-NA'VE患者
6. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
7. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
8. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study [O] . P. L. Zinzani, J. M. Vose, M. S. Czuczman, -1

机译：来那度胺在复发/难治性套细胞淋巴瘤中的长期随访：NHL-003研究的亚组分析
9. Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT) [O] . Nieto Y., Jones R.B., Popat U., 2012

机译：吉西他滨，白消安和美法仑（Gem / Bu / Mel）是一种新型的高剂量化学疗法（HDC）方案，在接受自体干细胞移植（ASCT）的难治性或低危复发非霍奇金淋巴瘤（NHL）患者中具有高活性）
10. Patient Race and Outcome Preferences as Predictors of Urologists' Treatment Recommendations and Referral Patterns in Early-Stage Prostate Cancer; Final rept. 31 Oct 2004-30 Oct 2007 [R] . Denberg, T. 2007

机译：患者种族和结果偏好作为泌尿科医师治疗建议和早期前列腺癌转诊模式的预测因子;最终的评论。 2004年10月31日至2007年10月30日

Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT

著录项

相似文献

相关主题

期刊订阅